Scholarlink

Background <p>Squamous cell carcinoma of the tongue (TSCC) is an aggressive malignancy with few therapeutic modalities available. Cisplatin, a commonly used chemotherapeutic drug, is often associated with significant toxicities and resistance. The use of an exosome-enriched fraction of extracellular vesicles (EVs) as a drug delivery system has become an attractive way to potentiate therapeutic effects and decrease toxicity. In particular, our focus is to study the therapeutic effect of cisplatin-loaded EVs obtained from umbilical cord mesenchymal stem cells (UC-MSCs) on TSCC. The goal is to assess the functionality of cancer cells and to characterize the EVs loaded with cisplatin.</p> Materials and methods <p>Cisplatin was incorporated into EVs derived from UC-MSCs. Characterization was performed using transmission electron microscopy (TEM) for morphology, BCA assay for protein quantification, and HPLC for drug loading efficiency. The presence of apoptotic bodies was evaluated using cytotoxicity assays and inverted phase-contrast microscopy to assess the effects of EV-encapsulated cisplatin on TSCC cells.</p> Results <p>Cisplatin-encapsulated EVs presented a statistically significantly more cytotoxic effect on cancer cells than unencapsulated cisplatin, with the half-maximal inhibitory concentration (IC50) of the EV formulation (1.64&#xa0;µg/mL) representing a 25% enhancement in potency compared to free cisplatin (2.18&#xa0;µg/mL; <i>p</i> &lt; 0.05). Conclusion: UC-MSCs-derived EVs represent a promising strategy for a more localized and effective cisplatin delivery with potential improvement in TSCC chemotherapy efficacy while minimizing conventional chemotherapy-related side effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A novel extracellular vesicle (EV)-based nanodrug for tongue squamous cell carcinoma: in vitro efficacy in HNO-97 cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Shaimaa Ali Hamouda Ali El Basuony,
  • Doha Mohammed Afifi,
  • Nihal Darwish,
  • Heba Khaled

摘要

Background

Squamous cell carcinoma of the tongue (TSCC) is an aggressive malignancy with few therapeutic modalities available. Cisplatin, a commonly used chemotherapeutic drug, is often associated with significant toxicities and resistance. The use of an exosome-enriched fraction of extracellular vesicles (EVs) as a drug delivery system has become an attractive way to potentiate therapeutic effects and decrease toxicity. In particular, our focus is to study the therapeutic effect of cisplatin-loaded EVs obtained from umbilical cord mesenchymal stem cells (UC-MSCs) on TSCC. The goal is to assess the functionality of cancer cells and to characterize the EVs loaded with cisplatin.

Materials and methods

Cisplatin was incorporated into EVs derived from UC-MSCs. Characterization was performed using transmission electron microscopy (TEM) for morphology, BCA assay for protein quantification, and HPLC for drug loading efficiency. The presence of apoptotic bodies was evaluated using cytotoxicity assays and inverted phase-contrast microscopy to assess the effects of EV-encapsulated cisplatin on TSCC cells.

Results

Cisplatin-encapsulated EVs presented a statistically significantly more cytotoxic effect on cancer cells than unencapsulated cisplatin, with the half-maximal inhibitory concentration (IC50) of the EV formulation (1.64 µg/mL) representing a 25% enhancement in potency compared to free cisplatin (2.18 µg/mL; p < 0.05). Conclusion: UC-MSCs-derived EVs represent a promising strategy for a more localized and effective cisplatin delivery with potential improvement in TSCC chemotherapy efficacy while minimizing conventional chemotherapy-related side effects.